| |
 | |  |
|
| |
|
Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
(04/Jun/2009)
|
|
(Thomas Jefferson University) A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a priority report in Cancer Research, published by researchers at Thomas Jefferson University. (Source: EurekAlert! - Cancer)
|
|
|
|
Detection Of Digestive Cancers In Multiple Organs Using Improved DNA Stool Test
(03/Jun/2009)
|
|
Mayo Clinic researchers have demonstrated that a noninvasive screening test can detect not only colorectal cancer but also the common cancers above the colon -- including pancreas, stomach, biliary and esophageal cancers. This is one of more than 100 Mayo Clinic studies being presented at Digestive Disease Week 2009 in Chicago, May 30 - June 4. (Source: Health News from Medical News Today)
|
|
|
|
Stool test shows promise in detecting many cancers
(02/Jun/2009)
|
|
CHICAGO (Reuters) - Using just a stool sample, doctors may be able to detect colon and many other cancers of the digestive tract including stomach, pancreatic, bile duct and esophageal cancer, U.S. researchers said on Tuesday. (Source: Reuters: Health)
|
|
|
|
New Pathology Tests Double Sensitivity To Detect Bile Duct And Pancreatic Cancers
(02/Jun/2009)
|
|
Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published in the June issue of Gastroenterology. (Source: Health News from Medical News Today)
|
|
|
|
Improved DNA stool test could detect digestive cancers in multiple organs
(02/Jun/2009)
|
|
(Mayo Clinic) Mayo Clinic researchers have demonstrated that a noninvasive screening test can detect not only colorectal cancer but also the common cancers above the colon -- including pancreas, stomach, biliary and esophageal cancers. This is one of more than 100 Mayo Clinic studies being presented at Digestive Disease Week 2009 in Chicago, May 30 through June 4. (Source: EurekAlert! - Cancer)
|
|
|
|
UK diabetics to be first in the world to try out new insulin pump
(02/Jun/2009)
|
|
UK DIABETICS will be the first to use a new insulin pump mimicking the human pancreas. (Source: Scotsman.com News - Health)
|
|
|
|
Mayo Clinic finds new pathology tests double sensitivity to detect bile duct and pancreatic cancers
(01/Jun/2009)
|
|
(Mayo Clinic) Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. Researchers have developed new tests that double the ability to detect bile duct and pancreatic cancers, according to a Mayo Clinic study published in the June issue of Gastroenterology. (Source: EurekAlert! - Medicine and Health)
|
|
|
|
Scottsdale Healthcare Is West's Only Clinical Research Site For "Dream Team" Pancreatic Cancer Research Studies
(01/Jun/2009)
|
|
Scottsdale Healthcare, through its strategic alliance with the Translational Genomics Research Institute (TGen), is one of three clinical research sites in the United States that will participate in a three-year investigation into new approaches to treating pancreatic cancer, the fourth leading cause of cancer death in the U.S. (Source: Health News from Medical News Today)
|
|
|
|
2009 American Transplant Congress (ATC), Boston
(01/Jun/2009)
|
|
NewYork-Presbyterian Hospital/Weill Cornell Medical Center physician-scientists are presenting exciting new research at the 2009 American Transplant Congress in Boston from May 30 to June 3. Dr. Sandip Kapur, chief of transplant surgery and director of kidney and pancreas transplant programs at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr. (Source: Health News from Medical News Today)
|
|
|
|
Novel Targeted Radiation Therapy From Immunomedics Produces Objective Responses in Pancreatic Cancer
(31/May/2009)
|
|
ORLANDO, Fla., May 31, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported a 30% objective response rate in 10 evaluable patients with inoperable, advanced pancreatic cancer treated with a novel targeted radiation therapy developed by the Company in combination with gemcitabine. Interim results from the ongoing Phase Ib dose-escalation study were presented at the 2009 Annual Meeting of American Society
|
|
|
| |
| | |
|